Algernon Pharmaceuticals Inc
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of s… Read more
Algernon Pharmaceuticals Inc (AGNPF) - Total Assets
Latest total assets as of November 2025: $4.93 Million USD
Based on the latest financial reports, Algernon Pharmaceuticals Inc (AGNPF) holds total assets worth $4.93 Million USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Algernon Pharmaceuticals Inc - Total Assets Trend (2016–2025)
This chart illustrates how Algernon Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Algernon Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (August 2025)
Algernon Pharmaceuticals Inc's total assets of $4.93 Million consist of 11.4% current assets and 88.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.29 Million | 88.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Algernon Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Algernon Pharmaceuticals Inc's current assets represent 11.4% of total assets in 2025, a decrease from 75.3% in 2016.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, down from 70.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 23.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 88.0% of total assets.
Algernon Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Algernon Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Algernon Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Algernon Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Algernon Pharmaceuticals Inc is currently not profitable relative to its asset base.
Algernon Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.25 | 0.23 | 3.60 |
| Quick Ratio | 0.25 | 0.23 | 3.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.83 Million | $ -1.44 Million | $ 4.09 Million |
Algernon Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Algernon Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.68 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 23.7% |
| Total Assets | $4.88 Million |
| Market Capitalization | $1.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Algernon Pharmaceuticals Inc's assets below their book value (0.35 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Algernon Pharmaceuticals Inc's assets grew by 23.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Algernon Pharmaceuticals Inc (2016–2025)
The table below shows the annual total assets of Algernon Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $4.88 Million | +23.67% |
| 2024-08-31 | $3.94 Million | -5.95% |
| 2023-08-31 | $4.19 Million | -48.49% |
| 2022-08-31 | $8.14 Million | -19.70% |
| 2021-08-31 | $10.14 Million | -20.95% |
| 2020-08-31 | $12.82 Million | +140.23% |
| 2019-08-31 | $5.34 Million | +275.16% |
| 2018-08-31 | $1.42 Million | -13.06% |
| 2017-08-31 | $1.64 Million | -28.00% |
| 2016-08-31 | $2.27 Million | -- |